Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 5/2008

01-05-2008 | Original Paper

Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma

Authors: Hui Wang, Ke Pan, Hua-kun Zhang, De-sheng Weng, Jun Zhou, Jian-jun Li, Wei Huang, Hai-feng Song, Min-shan Chen, Jian-chuan Xia

Published in: Journal of Cancer Research and Clinical Oncology | Issue 5/2008

Login to get access

Abstract

Purpose

Recent studies have identified polycomb-group gene Bmi-1 as oncogene in the generation of mouse pre-cell lymphomas, and overexpression of Bmi-1 has been found in several human tumor with the disease progress and poor prognosis of the cancer patients.

Methods

In present study, we investigated Bmi-1 expression and its prognostic significance in hepatocellular carcinoma (HCC) by performing immunohistochemical analysis, using a total of 137 HCC clinical tissue samples.

Results

High Bmi-1 expression (Bmi-1 2+ or 3+) was shown in 29.9% cases. The positive immuno-staining of Bmi-1 was not only in well/moderately-differentiated tumor cells, but also in surrounding noncancerous or cirrhotic liver tissue. Bmi-1 expression level did not correlate with any clinicopathological parameters. However, survival analysis showed that the high-Bmi-1 group had a significantly shorter overall survival time than the low-Bmi-1 group (P = 0.047). Multivariate analysis after 24 months revealed that Bmi-1 expression was a significant and independent prognostic parameter (P = 0.002) for HCC patients.

Conclusions

Our study indicated that Bmi-1 could be a candidate biomarker for long-term survival in HCC.
Literature
go back to reference Bosch FX, Ribes J, Cleries R, Diaz M (2005) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9:191–211PubMedCrossRef Bosch FX, Ribes J, Cleries R, Diaz M (2005) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9:191–211PubMedCrossRef
go back to reference Breuer RH, Snijders PJ, Smit EF, Sutedja TG, Sewalt RG, Otte AP, van Kemenade FJ, Postmus PE, Meijer CJ, Raaphorst FM (2004) Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 6:736–743PubMedCrossRef Breuer RH, Snijders PJ, Smit EF, Sutedja TG, Sewalt RG, Otte AP, van Kemenade FJ, Postmus PE, Meijer CJ, Raaphorst FM (2004) Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 6:736–743PubMedCrossRef
go back to reference Chowdhury M, Mihara K, Yasunaga S, Ohtaki M, Takihara Y, Kimura A (2007) Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia. Leukemia 21:1116–1122PubMed Chowdhury M, Mihara K, Yasunaga S, Ohtaki M, Takihara Y, Kimura A (2007) Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia. Leukemia 21:1116–1122PubMed
go back to reference Cui H, Hu B, Li T, Ma J, Alam G, Gunning WT, Ding HF (2007) Bmi-1 is essential for the tumorigenicity of neuroblastoma cells. Am J Pathol 170:1370–1378PubMedCrossRef Cui H, Hu B, Li T, Ma J, Alam G, Gunning WT, Ding HF (2007) Bmi-1 is essential for the tumorigenicity of neuroblastoma cells. Am J Pathol 170:1370–1378PubMedCrossRef
go back to reference Dimri GP, Martinez JL, Jacobs JJ, Keblusek P, Itahana K, Van Lohuizen M, Campisi J, Wazer DE, Band V (2002) The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res 62:4736–4745PubMed Dimri GP, Martinez JL, Jacobs JJ, Keblusek P, Itahana K, Van Lohuizen M, Campisi J, Wazer DE, Band V (2002) The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res 62:4736–4745PubMed
go back to reference Haupt Y, Bath ML, Harris AW, Adams JM (1993) Bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis. Oncogene 8:3161–3164PubMed Haupt Y, Bath ML, Harris AW, Adams JM (1993) Bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis. Oncogene 8:3161–3164PubMed
go back to reference Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M (1999a) The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397:164–168PubMedCrossRef Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M (1999a) The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397:164–168PubMedCrossRef
go back to reference Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M (1999b) Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 13:2678–2690PubMedCrossRef Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M (1999b) Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 13:2678–2690PubMedCrossRef
go back to reference Kang MK, Kim RH, Kim SJ, Yip FK, Shin KH, Dimri GP, Christensen R, Han T, Park NH (2007) Elevated Bmi-1 expression is associated with dysplastic cell transformation during oral carcinogenesis and is required for cancer cell replication and survival. Br J Cancer 96:126–133PubMedCrossRef Kang MK, Kim RH, Kim SJ, Yip FK, Shin KH, Dimri GP, Christensen R, Han T, Park NH (2007) Elevated Bmi-1 expression is associated with dysplastic cell transformation during oral carcinogenesis and is required for cancer cell replication and survival. Br J Cancer 96:126–133PubMedCrossRef
go back to reference Kim JH, Yoon SY, Jeong SH, Kim SY, Moon SK, Joo JH, Lee Y, Choe IS, Kim JW (2004a) Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast 13:383–388PubMedCrossRef Kim JH, Yoon SY, Jeong SH, Kim SY, Moon SK, Joo JH, Lee Y, Choe IS, Kim JW (2004a) Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast 13:383–388PubMedCrossRef
go back to reference Kim JH, Yoon SY, Kim CN, Joo JH, Moon SK, Choe IS, Choe YK, Kim JW (2004b) The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 203:217–224PubMedCrossRef Kim JH, Yoon SY, Kim CN, Joo JH, Moon SK, Choe IS, Choe YK, Kim JW (2004b) The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 203:217–224PubMedCrossRef
go back to reference Mohty M, Yang AS, Szydlo RM, Apperley JF, Melo JV (2007) The polycomb group BMI-1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 110:380–383PubMedCrossRef Mohty M, Yang AS, Szydlo RM, Apperley JF, Melo JV (2007) The polycomb group BMI-1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 110:380–383PubMedCrossRef
go back to reference Neo SY, Leow CK, Vega VB, Long PM, Islam AF, Lai PB, Liu ET, Ren EC (2004) Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach. Hepatology 39:944–953PubMedCrossRef Neo SY, Leow CK, Vega VB, Long PM, Islam AF, Lai PB, Liu ET, Ren EC (2004) Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach. Hepatology 39:944–953PubMedCrossRef
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: globocan 2000. Int J Cancer 94:153–156PubMedCrossRef Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: globocan 2000. Int J Cancer 94:153–156PubMedCrossRef
go back to reference Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, Fu LW, Huang WL, Dimri GP, Band V, Zeng YX (2006) Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 66:6225–6232PubMedCrossRef Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, Fu LW, Huang WL, Dimri GP, Band V, Zeng YX (2006) Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 66:6225–6232PubMedCrossRef
go back to reference Steele JC, Torr EE, Noakes KL, Kalk E, Moss PA, Reynolds GM, Hubscher SG, van Lohuizen M, Adams DH, Young LS (2006) The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens. Br J Cancer 95:1202–1211PubMedCrossRef Steele JC, Torr EE, Noakes KL, Kalk E, Moss PA, Reynolds GM, Hubscher SG, van Lohuizen M, Adams DH, Young LS (2006) The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens. Br J Cancer 95:1202–1211PubMedCrossRef
go back to reference Tateishi K, Ohta M, Kanai F, Guleng B, Tanaka Y, Asaoka Y, Tada M, Seto M, Jazag A, Lianjie L, Okamoto M, Isayama H, Tada M, Yoshida H, Kawabe T, Omata M (2006) Dysregulated expression of stem cell factor Bmi-1 in precancerous lesions of the gastrointestinal tract. Clin Cancer Res 12:6960–6966PubMedCrossRef Tateishi K, Ohta M, Kanai F, Guleng B, Tanaka Y, Asaoka Y, Tada M, Seto M, Jazag A, Lianjie L, Okamoto M, Isayama H, Tada M, Yoshida H, Kawabe T, Omata M (2006) Dysregulated expression of stem cell factor Bmi-1 in precancerous lesions of the gastrointestinal tract. Clin Cancer Res 12:6960–6966PubMedCrossRef
go back to reference Thomas MB, Zhu AX (2005) Hepatocellular carcinoma: the need for progress. J Clin Oncol 23:2892–2899PubMedCrossRef Thomas MB, Zhu AX (2005) Hepatocellular carcinoma: the need for progress. J Clin Oncol 23:2892–2899PubMedCrossRef
go back to reference van Galen JC, Muris JJ, Oudejans JJ, Vos W, Giroth CP, Ossenkoppele GJ, Otte AP, Raaphorst FM, Meijer CJ (2007) Expression of the polycomb-group gene Bmi-1 is related to an unfavourable prognosis in primary nodal DLBCL. J Clin Pathol 60:167–172PubMedCrossRef van Galen JC, Muris JJ, Oudejans JJ, Vos W, Giroth CP, Ossenkoppele GJ, Otte AP, Raaphorst FM, Meijer CJ (2007) Expression of the polycomb-group gene Bmi-1 is related to an unfavourable prognosis in primary nodal DLBCL. J Clin Pathol 60:167–172PubMedCrossRef
go back to reference van Leenders GJ, Dukers D, Hessels D, van den Kieboom SW, Hulsbergen CA, Witjes JA, Otte AP, Meijer CJ, Raaphorst FM (2007) Polycomb-group oncogenes EZH2, Bmi-1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 52:455–463PubMedCrossRef van Leenders GJ, Dukers D, Hessels D, van den Kieboom SW, Hulsbergen CA, Witjes JA, Otte AP, Meijer CJ, Raaphorst FM (2007) Polycomb-group oncogenes EZH2, Bmi-1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 52:455–463PubMedCrossRef
go back to reference van Lohuizen M, Frasch M, Wientjens E, Berns A (1991) Sequence similarity between the mammalian bmi-1 proto-oncogene and the Drosophila regulatory genes Psc and Su(z)2. Nature 353:353–355PubMedCrossRef van Lohuizen M, Frasch M, Wientjens E, Berns A (1991) Sequence similarity between the mammalian bmi-1 proto-oncogene and the Drosophila regulatory genes Psc and Su(z)2. Nature 353:353–355PubMedCrossRef
go back to reference Vonlanthen S, Heighway J, Altermatt HJ, Gugger M, Kappeler A, Borner MM, van Lohuizen M, Betticher DC (2001) The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 84:1372–1376PubMedCrossRef Vonlanthen S, Heighway J, Altermatt HJ, Gugger M, Kappeler A, Borner MM, van Lohuizen M, Betticher DC (2001) The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 84:1372–1376PubMedCrossRef
Metadata
Title
Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma
Authors
Hui Wang
Ke Pan
Hua-kun Zhang
De-sheng Weng
Jun Zhou
Jian-jun Li
Wei Huang
Hai-feng Song
Min-shan Chen
Jian-chuan Xia
Publication date
01-05-2008
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 5/2008
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-007-0316-8

Other articles of this Issue 5/2008

Journal of Cancer Research and Clinical Oncology 5/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.